Anthera Pharmaceuticals (Anthera Pharmaceuticals) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of May. 05, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Anthera Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.

Anthera Pharmaceuticals (OTCPK:ANTH) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Anthera Pharmaceuticals Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anthera Pharmaceuticals Inc (OTCPK:ANTH) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Comparable Companies

Traded in Other Exchanges

N/A

Address

25801 Industrial Boulevard, Suite B, Hayward, CA, USA, 94545

Website

http://www.anthera.com

Anthera Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. The company currently has one Phase 3-ready clinical program and two Phase 2 clinical programs. It was established in 2004.

Executives

Christopher S Henney	director	10505 ROSELLE STREET, SAN DIEGO CA 92121
Shanahan William R Jr	officer: Chief Medical Officer	10301 STELLA LINK HOUSTON TX 77025
Brian Mueller	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Paul F Truex	director	PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Charles V Olson	officer: Chief Technology Officer	25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545
Klara Dickinson	officer: Chief Regulatory Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Steven B Engle	director	C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
James Pennington	officer: Interim Chief Medical Officer	25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545
Hislop Colin	officer: Chief Medical Officer	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sanford S Zweifach	director	21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Christopher P. Lowe	officer: CFO and Chief Business Officer	2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Orbimed Capital Gp Iv Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022

Anthera Pharmaceuticals (Anthera Pharmaceuticals) Headlines

From GuruFocus

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-14-2010

Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets

By Marketwired Marketwired • 06-27-2018

Major US Indexes End Higher Monday

By Julie Young • 11-08-2021

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 08-12-2010

Anthera Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2010